ACHIEVE LIFE SCIENCES INC (ACHV)
Health Care · Clinical-stage biopharmaceuticals / smoking cessation therapeutics · NASDAQ
A clinical-stage biotech developing cytisinicline for smoking cessation and nicotine dependence, preparing for commercialization after completing key clinical trials.
What ACHIEVE LIFE SCIENCES INC does
Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of cytisinicline, a novel drug candidate for treating nicotine dependence and smoking cessation. The company is advancing cytisinicline through clinical trials, including the completed ORCA-OL trial, and is preparing for commercial launch while exploring additional indications beyond smoking cessation. The company is unprofitable and relies on capital raises and strategic partnerships to fund its development and commercialization efforts.
Themes: ["smoking cessation / nicotine dependence treatment","clinical-stage drug development","regulatory approval pathway (FDA)"]
Fundamentals
- Price$6.40 as of 2026-07-09 close
- Market cap$650M as of 2026-07-10
- 1-year return+170.0% as of 2026-07-09 close
- Net margin-94.7% as of 2026-07-10
- Gross margin-98.8% as of 2026-07-10
- ROE-193.5% as of 2026-07-10
- Debt / equity1.40 as of 2026-07-10
- Revenue growth (YoY)-89.3% as of 2026-07-10
- Beta2.28 as of 2026-07-10
Key risks (from latest filing)
["Successful development of cytisinicline is highly uncertain and regulatory approval is not guaranteed; clinical trial outcomes and timelines are unpredictable.","The company requires additional capital raises to advance development and commercialization programs, creating substantial funding and dilution risk.","Dependence on third-party manufacturers to receive and maintain FDA approval and provide timely, sufficient supply of cytisinicline could disrupt commercialization."]
Competitors & peers
- Pfizer (PFE) - Chantix/Champix (varenicline for smoking cessation)
- GlaxoSmithKline (GSK) - Nicoderm and NicoDerm CQ (nicotine replacement therapy)
- Novartis (NVS) - various smoking cessation products
- Phonex Pharmaceuticals - competing smoking cessation/nicotine dependence programs
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.